MX362218B - Derivados de pentilentetrazol. - Google Patents

Derivados de pentilentetrazol.

Info

Publication number
MX362218B
MX362218B MX2013012850A MX2013012850A MX362218B MX 362218 B MX362218 B MX 362218B MX 2013012850 A MX2013012850 A MX 2013012850A MX 2013012850 A MX2013012850 A MX 2013012850A MX 362218 B MX362218 B MX 362218B
Authority
MX
Mexico
Prior art keywords
anxiety
individuals
instance
compounds
pentylenetetrazole
Prior art date
Application number
MX2013012850A
Other languages
English (en)
Other versions
MX2013012850A (es
Inventor
Lien Lyndon
Original Assignee
Balance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Balance Therapeutics Inc filed Critical Balance Therapeutics Inc
Publication of MX2013012850A publication Critical patent/MX2013012850A/es
Publication of MX362218B publication Critical patent/MX362218B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan los compuestos que tienen la fórmula (I) (ver Fórmula (I) en donde los radicales R1, R2, R3, R4, R5, R6, R7, R8, R9 y R10 son como se describe en la presente, y una sal farmacéutica de estos. También se proporcionan las composiciones farmacéuticas que contienen los compuestos y los métodos para su uso, por ejemplo, para tratar senilidad, confusión senil, psicosis, psiconeurosis cuando están presentes la ansiedad y tensión nerviosa, arterioesclerosis cerebral, náusea, depresión, fatiga, debilitación, trastornos conductuales leves, irritabilidad, inestabilidad emocional, actitudes antisociales, ansiedad, vértigo o incontinencia, o síntomas de lo anterior, o para mejorar la función cognitiva de los individuos, por ejemplo, en individuos con síndrome Down y otros estados.
MX2013012850A 2011-05-04 2012-05-03 Derivados de pentilentetrazol. MX362218B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161482533P 2011-05-04 2011-05-04
PCT/US2012/036217 WO2012151343A1 (en) 2011-05-04 2012-05-03 Pentylenetetrazole derivatives

Publications (2)

Publication Number Publication Date
MX2013012850A MX2013012850A (es) 2014-04-30
MX362218B true MX362218B (es) 2019-01-09

Family

ID=46178772

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012850A MX362218B (es) 2011-05-04 2012-05-03 Derivados de pentilentetrazol.

Country Status (13)

Country Link
US (2) US9453020B2 (es)
EP (1) EP2705013B1 (es)
JP (3) JP6092849B2 (es)
CN (1) CN103635446B (es)
AU (3) AU2012250776B2 (es)
CA (1) CA2835018C (es)
DK (1) DK2705013T3 (es)
ES (1) ES2579319T3 (es)
HK (1) HK1195050A1 (es)
IL (2) IL229218A (es)
MX (1) MX362218B (es)
WO (1) WO2012151343A1 (es)
ZA (1) ZA201408423B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151343A1 (en) * 2011-05-04 2012-11-08 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
US10688103B2 (en) * 2014-04-15 2020-06-23 Balance Therapeutics, Inc. Methods for treating hypersomnia
US11529358B2 (en) 2017-05-10 2022-12-20 Emory University Treatment of conditions associated with myotonic dystrophy
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
CN112979665B (zh) * 2021-02-07 2021-11-19 南通大学 一种灰黄霉素施密特重排衍生物及其制备方法
CN112920193B (zh) * 2021-02-07 2021-11-16 南通大学 一种灰黄霉素四唑衍生物及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3062720A (en) 1959-05-20 1962-11-06 Philips Roxane Sustained release pharmaceutical tablet
US3247066A (en) 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4777049A (en) 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4663308A (en) 1984-07-18 1987-05-05 Medical College Of Ohio Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (es) 1989-07-28 1992-01-15 Debiopharm Sa
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
ATE236655T1 (de) 1993-01-06 2003-04-15 Kinerton Ltd Ionische molekularkonjugate von bioabbaubaren polyestern und bioaktiven polypeptiden
WO1995026325A2 (en) * 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
RU2165942C2 (ru) 1996-04-23 2001-04-27 Кинертон Лимитид Биоразрушаемый сложный полиэфир и способ его получения (варианты)
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
US6217904B1 (en) 1999-04-06 2001-04-17 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant
US6645525B1 (en) 1999-06-23 2003-11-11 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
DK1204429T3 (da) 1999-08-18 2004-03-08 Sod Conseils Rech Applic Præparat til forsinket frigivelse af et peptid
DE60001623T2 (de) * 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
WO2002058672A2 (en) 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
AU2002258563A1 (en) 2001-03-19 2002-10-03 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained release
EP1480618B1 (en) 2002-03-04 2009-06-03 Ipsen Pharma Sustained release drug formulations containing a carrier peptide
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
ES2573733T3 (es) 2006-05-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento farmacológico del deterioro cognitivo
AU2007285845A1 (en) * 2006-08-16 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of opioid analgesics
US8946206B2 (en) 2010-12-17 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improving cognitive function
WO2012151343A1 (en) * 2011-05-04 2012-11-08 Balance Therapeutics, Inc. Pentylenetetrazole derivatives

Also Published As

Publication number Publication date
WO2012151343A1 (en) 2012-11-08
IL248589A0 (en) 2016-12-29
EP2705013A1 (en) 2014-03-12
IL229218A0 (en) 2014-01-30
AU2017219099A1 (en) 2017-09-14
CN103635446B (zh) 2016-02-03
CA2835018C (en) 2020-04-21
AU2012250776B2 (en) 2017-06-15
JP2017105821A (ja) 2017-06-15
ES2579319T3 (es) 2016-08-09
CA2835018A1 (en) 2012-11-08
CN103635446A (zh) 2014-03-12
AU2019213325A1 (en) 2019-08-22
JP6092849B2 (ja) 2017-03-08
MX2013012850A (es) 2014-04-30
EP2705013B1 (en) 2016-03-30
JP2019006819A (ja) 2019-01-17
JP2014513130A (ja) 2014-05-29
AU2017219099B2 (en) 2019-05-30
AU2012250776A1 (en) 2013-12-05
US9951076B2 (en) 2018-04-24
HK1195050A1 (zh) 2014-10-31
US9453020B2 (en) 2016-09-27
IL229218A (en) 2016-11-30
DK2705013T3 (en) 2016-07-18
IL248589A (en) 2017-09-28
US20140343040A1 (en) 2014-11-20
NZ617347A (en) 2015-11-27
ZA201408423B (en) 2016-09-28
US20170044165A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
MX362218B (es) Derivados de pentilentetrazol.
CY1117045T1 (el) Ενωσεις κινουκλιδινης ως προσδετες του νικοτινικου υποδοχεα ακετυλχολινης αλφα-7
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
MX2014006027A (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
HRP20130614T1 (en) Novel pyrazole-substituted arylamides
EA201390971A1 (ru) ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
IN2014CN03250A (es)
TW200740773A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
TN2011000339A1 (en) Poly (adp-ribose) polymerase (parp) inhibitors
MY183977A (en) Cytotoxic benzodiazepine derivatives
SG195085A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
MX2014006210A (es) Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
NZ588121A (en) Novel estrogen receptor ligands
PH12015500457A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
NZ600874A (en) Fluorinated derivatives of deferiprone
PT2139334E (pt) Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
ATE446089T1 (de) 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika
MX350862B (es) Acidos de piperidinil naftilacetico.
MX2015004285A (es) Derivado de imidazol.
PH12015500012B1 (en) Benzodioxole derivative and preparation method and use thereof

Legal Events

Date Code Title Description
FG Grant or registration